YOLFTbeta
Monopar Therapeutics Inc

Monopar Therapeutics Inc

MNPR · NASDAQ · Healthcare / Biotechnology

72.00USD-0.68 (-0.94%)

Price History

Full chart

Market Stats

Previous Close72.68
Open72.93
Day Range67.70 – 73.67
52-Week Range50.07 – 124.82
Volume203.21K
Market Cap561.94M
P/E (TTM)0.00
Forward P/E0.00
EPS-2.20
Dividend Yield0.00%
Beta1.50
50-Day Avg109.53
200-Day Avg76.41

About

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Chandler D. Robinson M.B.A., M.D., M.Sc.
  • Employees22
  • Headquarters1000 Skokie Boulevard, Wilmette, IL, United States, 60091, USA
  • Websitehttps://www.monopartx.com

Leadership

  • Dr. Christopher M. Starr Ph.D.Co-Founder & Independent Executive Chairman of the Board · b. 1952
  • Dr. Chandler D. Robinson M.B.A., M.D., M.Sc.Co-Founder, CEO, President & Director · b. 1984
  • Mr. Quan Anh VuCFO, Principal accounting officer, Principal financial officer, Secretary & Treasurer · b. 1972
  • Mr. Andrew J. Cittadine M.B.A.Chief Operating Officer · b. 1972
  • Dr. Patrice P. Rioux M.D., Ph.D.Acting Chief Medical Officer · b. 1951
  • Ms. Susan RodriguezChief Commercial & Strategy Officer · b. 1962
  • Dr. Jeffrey D. Kent FACG, FACP, M.D.Executive Vice President of Head of Medical Affairs · b. 1962

Financials

Income Statement

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-0000122.40K00000
Growth (%)-------100.00%----
Gross Profit-----122.40K-----
Gross Margin-----100.00%-----
Operating Expense-----6.63M-----
Operating Income-689.00K-1.19M-16.60M-3.40M-4.32M-6.51M-9.13M-10.54M-8.83M-16.16M-16.70M
Operating Margin------5317.71%-----
EBITDA1.25K-1.19M-16.60M-3.20M-4.32M-6.30M-9.08M-10.52M-8.40M-15.59M-13.72M
EBITDA Margin------5150.79%-----
Net Income-687.00K-1.19M-16.55M-3.23M-4.13M-6.30M-9.08M-10.49M-8.40M-15.59M-13.72M
Net Income Margin------5150.79%-----
R&D101.49K280.36K15.44M1.77M1.97M4.07M6.49M7.59M5.60M13.01M9.90B
R&D as % of Total Revenue-----3321.24%-----
Interest Expense07.23K48.26K103.22K98.89K81.90K24.02K21.24K---
Interest Expense % of Total Revenue-----66.91%-----

Balance Sheet

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.83M2.90M9.93M7.32M13.35M16.87M20.52M13.23M7.35M60.29M140.72M
Total Liabilities73.84K64.51K311.87K399.55K724.16K1.18M1.58M3.14M1.76M5.25M2.89M
Total Equity2.75M2.83M9.62M6.92M12.63M15.69M18.94M10.09M5.59M55.04M137.83M
Cash2.01M2.07M8.98M6.89M13.21M16.74M20.30M8.19M7.27M45.82M61.83M
Total Debt-------8.41K--154.92K
Net Debt-2.01M-2.07M-8.98M-6.89M-13.21M-16.74M-20.30M-8.18M-7.27M-45.82M-61.68M

Cash Flow

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-636.33K-1.19M-2.63M-2.89M-3.02M-4.66M-7.32M-7.23M-7.86M-6.40M-12.20M
Investing Cash Flow--------4.92M4.93M-14.34M-63.45M
Financing Cash Flow3.44M1.26M9.54M-206.27K9.35M8.18M10.88M32.87K2.03M59.29M91.57M
Capital Expenditure00000410300
Free Cash Flow-636.33K-1.19M-2.63M-2.89M-3.02M-4.66M-7.32M-7.23M-7.86M-6.40M-12.20M
FCF to OCF100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%

Earnings

Report DateAug 9, 2018Nov 9, 2018Feb 26, 2019May 10, 2019Aug 8, 2019Dec 23, 2019Mar 27, 2020May 7, 2020Aug 6, 2020Nov 12, 2020Mar 25, 2021May 13, 2021Aug 12, 2021Nov 12, 2021Mar 24, 2022May 12, 2022Aug 11, 2022Nov 10, 2022Mar 23, 2023May 11, 2023Aug 10, 2023Nov 9, 2023Mar 28, 2024May 9, 2024Aug 9, 2024Nov 8, 2024Mar 26, 2025May 13, 2025Aug 12, 2025Nov 13, 2025Mar 27, 2026May 15, 2026Aug 12, 2026Nov 12, 2026
EPS Estimate0.000.000.000.000.000.00-0.35-0.11-1.25-0.75-0.75-0.19-1.02-1.12-0.92-0.22-1.05-1.07-0.20-1.08-0.95-0.95-0.15-0.85-0.47-1.17-0.42-0.57-0.48-0.40-0.51-0.90-0.67-0.86
EPS Actual-0.06-0.05-0.06-0.10-0.07-0.08-0.57-0.10-0.70-0.75-0.95-0.16-0.85-1.00-1.05-0.19-1.10-0.95-0.23-0.95-0.80-0.70-0.12-0.50-0.50-1.85-2.75-0.38-0.35-0.48-0.61-0.46-0.62-
Surprise-------62.86%9.09%44.00%0.00%-26.67%15.79%16.67%10.71%-14.13%13.64%-4.76%11.21%-15.00%12.04%15.79%26.32%20.00%41.18%-6.38%-58.12%-554.76%33.33%27.08%-20.00%-19.61%48.75%7.46%-
Timing-----After-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hours-Pre-marketAfter-hours

Key Statistics & Ratios

Market Cap561.94M
Enterprise Value463.39M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book4.57
EPS-2.20
Book Value19.50
Revenue (TTM)0
Gross Profit (TTM)0
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-19.50%
Return on Assets-14.64%
Shares Outstanding6.71M
Shares Float4.48M
Beta1.50
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 5 analystsTarget 129.92
  • Strong Buy
    2
  • Buy
    2
  • Hold
    1

Ownership Breakdown

Institutions
95.01%
Insiders
23.37%
Retail / Other
0.00%

Top Institutional Holders

  • HHG PLC
    1.32M19.63%
  • RA Capital Management, LLC
    667.21K9.94%
  • Deerfield Management Co
    323.75K4.82%
  • BlackRock Inc
    316.57K4.72%
  • Saturn V Capital Management LLC
    311.98K4.65%
  • Siren, L.L.C.
    270.12K4.02%
  • ADAR1 Capital Management LLC
    264.28K3.94%
  • Polar Capital Holdings PLC
    226.53K3.37%
  • Vanguard Capital Management, LLC
    218.46K3.25%
  • Adage Capital Partners Gp LLC
    209.19K3.12%
  • TCG Crossover Management, LLC
    203.33K3.03%
  • Wellington Management Company LLP
    158.44K2.36%
  • Balyasny Asset Management LLC
    136.44K2.03%
  • Alyeska Investment Group, L.P.
    100.00K1.49%
  • Geode Capital Management, LLC
    99.92K1.49%
  • Vivo Capital, LLC
    90.50K1.35%

Top Fund Holders

  • Polar Capital Biotech S Inc
    203.13K3.03%
  • Vanguard MStar Total Stk Mkt Idx Invest
    159.79K2.38%
  • Janus Henderson Hrzn Biotec E2 USD
    129.27K1.93%
  • iShares Russell 2000 ETF
    116.96K1.74%

Stock Splits

  • Aug 13, 20241:5